Melanie Stein, ND

Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral intolerance through membrane lipid therapy.

This case report describes a 34-year-old woman with severe, treatment-refractory mast cell activation syndrome despite normal tryptase and urinary mediator studies. A series of intravenous phosphatidylcholine infusions targeting membrane integrity and phospholipid signaling was temporally associated with reduced reactivity, expanded dietary tolerance, and restoration of oral medication tolerance, supporting further investigation of membrane-directed strategies in refractory MCAS.

Abstract

Mast Cell Activation Syndrome (MCAS) is characterized by episodic multisystem symptoms resulting from inappropriate mast cell mediator release and may occur despite normal conventional biomarkers. Phospholipid metabolism and membrane signaling dynamics play a central role in mast cell activation.  This case outlines a 34-year-old female with a history of Borrelia burgdorferi and Babesia duncani infection who presented with severe mast cell activation manifested by recurrent throat tightening, daily urticaria, tremors, muscle rigidity, diarrhea, cognitive dysfunction, anxiety, and near-universal food intolerance limited to chicken and rice. Chronic tick-borne infection and persistent immune activation were considered etiological contributors. Serum tryptase, 24-hour urinary N-methylhistamine, and urinary prostaglandin D2 were within reference ranges; plasma histamine was mildly elevated. Diagnosis was based on reproducible multisystem mediator-related symptoms and exclusion of alternative conditions. Due to profound oral intolerance, a series of 20 intravenous phosphatidylcholine infusions was administered. Progressive reduction in reactivity, improved dietary tolerance, and restoration of oral medication tolerance were observed, allowing subsequent antimicrobial therapy. This case supports further investigation of membrane-directed strategies within a naturopathic framework, emphasizing the correction of underlying drivers and the restoration of cellular integrity.

Introduction

Mast cell activation is a membrane-dependent process governed by receptor clustering, calcium flux, and phospholipid-mediated signaling.1-3 Degranulation requires coordinated phospholipid remodeling and receptor aggregation within lipid rafts.² Phosphatidylcholine (PC) serves as both a structural membrane component and a substrate for signaling pathways central to mast cell activation.¹ Hydrolysis of PC contributes to diacylglycerol generation and amplification of protein kinase C–dependent degranulation.¹ Glycerophospholipid metabolism, including upregulation of the Kennedy pathway enzyme Pcyt1a, is essential for sustained IgE-mediated mast cell activation.³ Although laboratory biomarkers may assist evaluation, MCAS remains a clinical diagnosis.⁴

Case Presentation

A 34-year-old female with prior Borrelia burgdorferi and Babesia duncani infection presented with progressive multisystem reactivity. Symptoms included recurrent throat tightening, daily urticaria, burning oral sensation, tremors, muscle rigidity, diarrhea, cognitive impairment, anxiety, and severe food intolerance limited to chicken and rice. She reacted to supplements and medications, even when compounded. Symptoms were persistent and significantly impairing.

Etiological Considerations

Chronic tick-borne infection was considered a contributing etiological factor through ongoing immune activation, cytokine signaling, and oxidative stress.⁵ Persistent inflammatory burden may promote lipid peroxidation and phospholipid remodeling, potentially lowering mast cell activation thresholds.

Diagnostic Assessment

Laboratory evaluation included:

• Serum tryptase within reference range (<11.4 ng/mL)
• 24-hour urinary N-methylhistamine within reference range
• Urinary prostaglandin D2 within reference range
• Plasma histamine: 2 ng/mL (reference <1.0 ng/mL)

Despite normal mediator testing, the patient met proposed clinical criteria for MCAS based on recurrent multisystem symptoms consistent with mast cell mediator release.⁴

Differential Diagnosis

• IgE-mediated food allergy: Near-universal reactivity and intolerance to inert compounds made isolated IgE-mediated allergy unlikely.
• Systemic mastocytosis: Normal tryptase and absence of clonal features reduced the likelihood.
• Autoimmune disease: No laboratory or clinical findings supported systemic autoimmune pathology.
• Primary psychiatric disorder: Objective urticaria and gastrointestinal symptoms supported an immunologic etiology.

The overall clinical pattern was most consistent with mast cell activation syndrome.

Therapeutic Intervention

Standard-dose H1 and H2 antihistamines, leukotriene modifiers, ketotifen, and low-dose naltrexone were not tolerated. Nebulized cromolyn sodium was tolerated. Given profound oral intolerance, intravenous phosphatidylcholine (40 mL per infusion) was administered over 20 treatments. Initial infusions contained PC alone, and glutathione was added after tolerance improved. Therapy was selected based on PC’s structural and signaling roles in mast cell membranes.

Outcomes and Follow-Up

Urticaria frequency decreased, throat-tightening episodes diminished, tremors improved, and cognitive clarity increased. Dietary tolerance expanded, and oral mast cell therapies became tolerable. The patient subsequently completed three months of botanical antimicrobial therapy without mast cell exacerbation. Improvement was sustained at follow-up.

Discussion

Phospholipid Signaling in Mast Cell Activation

Mast cell activation is fundamentally dependent on phospholipid-mediated signaling. Phosphatidylcholine (PC), the dominant structural phospholipid of mammalian cell membranes, serves not only as a membrane scaffold but also as a critical signaling substrate. During IgE–FcεRI cross-linking, phospholipases hydrolyze PC, generating diacylglycerol (DAG), a central second messenger in mast cell activation.¹ DAG activates protein kinase C (PKC), amplifying calcium-dependent degranulation and cytokine release.¹ PC has been demonstrated to be a quantitatively more significant source of activation-associated DAG than phosphatidylinositol in mast cells.¹ Recent evidence demonstrates that glycerophospholipid metabolism licenses IgE-mediated mast cell activation.³ Upregulation of the Kennedy pathway enzyme Pcyt1a during stimulation supports enhanced phosphatidylcholine synthesis, suggesting membrane remodeling is metabolically required for sustained degranulation.³

PLA2 and Amplification Cascades

Phospholipase A2 (PLA2) hydrolyzes membrane phospholipids, including PC, liberating arachidonic acid and lysophosphatidylcholine.⁶ Arachidonic acid serves as the precursor for prostaglandins and leukotrienes, potent inflammatory mediators implicated in MCAS symptomatology. Lysophosphatidylcholine increases intracellular calcium and potentiates mast cell secretion.⁶ PLA2 activation requires calcium-dependent translocation and MAP kinase–mediated phosphorylation. Persistent calcium flux and oxidative stress may lower activation thresholds.

Membrane Remodeling and Lipid Raft Dynamics

Lipid rafts are cholesterol- and sphingolipid-enriched microdomains that serve as organizing platforms for FcεRI clustering and signal propagation.² Alterations in raft composition influence receptor aggregation and downstream signaling intensity. Repeated degranulation cycles require membrane fusion and recycling, and oxidative lipid peroxidation may alter phospholipid composition and bilayer fluidity.

Membrane Lipid Replacement Hypothesis

Membrane lipid replacement strategies propose that exogenous phosphatidylcholine can integrate into cellular membranes, restoring phospholipid balance and improving bilayer fluidity.⁷,⁸ By replenishing damaged phospholipids, membrane stability may improve and activation thresholds may increase. This approach functions as a structural intervention to modify membrane composition and signaling dynamics. Evidence specific to mast cell disorders remains hypothesis-generating.

Mitochondrial Considerations

Mitochondrial membranes depend on intact phospholipid bilayers to maintain transmembrane potential.⁸ Oxidative damage may impair ATP production and increase reactive oxygen species, amplifying inflammatory cascades. Restoration of phospholipid integrity may indirectly influence mast cell stability through improved mitochondrial function. 

In this case, intravenous PC administration temporally preceded a reduction in mast cell reactivity and restoration of oral tolerance. While causation cannot be established, membrane-directed modulation warrants further investigation.

Limitations

This report describes a single patient and does not establish causality. Mast cell mediators were not serially reassessed. Controlled studies are required to evaluate membrane-directed interventions in refractory MCAS.

Conclusion

This case highlights that severe mast cell activation can present with profound clinical instability despite normal conventional mediator studies. In refractory phenotypes such as this, the clinical picture may reflect not only mediator excess but also altered activation thresholds driven by membrane-level signaling dynamics.

Phospholipids are not passive structural components. They regulate receptor clustering within lipid rafts, control membrane fluidity, and serve as substrates for second-messenger pathways that amplify calcium-dependent degranulation.1-3 Phosphatidylcholine, in particular, is central to mast cell activation signaling through its contribution to diacylglycerol generation and downstream protein kinase C activation, and it may be vulnerable to oxidative remodeling during chronic inflammatory states.¹ Repeated degranulation, persistent calcium flux, and oxidative stress may promote phospholipid depletion or peroxidation, increasing membrane permeability and sensitizing phospholipase-mediated amplification, including PLA2-dependent generation of arachidonic acid and lysophospholipids.⁶

Within this framework, membrane lipid replacement is conceptualized as a structural intervention. Administration of exogenous phosphatidylcholine may replenish damaged membrane phospholipid pools, improve bilayer fluidity, and stabilize raft organization, thereby raising the threshold for inappropriate activation and reducing amplification loops.2,7,8 Improved mitochondrial membrane integrity may also reduce redox-driven inflammatory signaling and support the energy demands required for mast cell quiescence.8 In this patient, the temporal association between intravenous phosphatidylcholine therapy and progressive reduction in daily reactivity, restoration of oral medication tolerance, and subsequent ability to treat underlying infectious drivers supports biologic plausibility for a membrane-stabilizing effect.

This report does not establish causality, and further study is needed to clarify which clinical phenotypes benefit most, define optimal dosing strategies, and determine whether changes in lipid composition or mediator profiles can be demonstrated prospectively. Nevertheless, this case supports continued investigation of phospholipid remodeling and membrane-directed therapies as an adjunctive approach for severe, treatment-refractory MCAS.

Dr. Melanie Stein, ND is a licensed Naturopathic Physician in Portland, Oregon and a recognized leader in Cell Membrane Therapy for the treatment of complex and chronic illness. She specializes in restoring health at the cellular level—repairing and revitalizing cell membranes to improve energy production, enhance detoxification, and restore healthy communication between cells. This therapy addresses the very foundation of health, helping patients recover from the cellular damage caused by chronic infections, mold toxicity, inflammation, and environmental exposures.

Her approach blends cutting-edge therapies with a deeply individualized care model. By addressing root causes—such as co-infections, inflammatory cascades, and toxic exposures—Dr. Stein creates treatment plans that repair the body’s foundation while supporting whole-body detoxification, organ function, and inflammation modulation. This targeted cellular repair not only accelerates healing but also helps patients better tolerate treatment by minimizing die-off reactions and supporting mitochondrial health.

References

1. Kennerly DA. Phosphatidylcholine is a quantitatively more important source of increased 1,2-diacylglycerol than is phosphatidylinositol in mast cells. J Immunol. 1990;144(10):3912-3919.
2. Sezgin E, Levental I, Mayor S, Eggeling C. The mystery of membrane organization: composition, regulation and physiological relevance of lipid rafts. Nat Rev Mol Cell Biol. 2017;18(6):361-374.
3. Xia Y, Bin P, Zhou Y, et al. Glycerophospholipid metabolism licenses IgE-mediated mast cell degranulation. Cell Rep. 2025;44(6):115742.
4. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes. Int Arch Allergy Immunol. 2012;157(3):215-225.
5. O’Neal AJ, Butler LR, Rolandelli A, et al. Lipid hijacking: a unifying theme in vector-borne diseases. eLife. 2020;9:e61675.
6. Martin TW, Lagunoff D. Interactions of lysophospholipids and mast cells. Nature. 1979;279(5710):250-252.
7. Nicolson GL. Membrane lipid replacement for chronic illnesses and aging. Clin Lipidol. 2012;7(1):1-14.
8. Nicolson GL. Membrane lipid replacement and mitochondrial function. Aging Dis. 2015;6(6):456-466.